Navigation Links
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Date:9/9/2008

SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will host a science briefing on Tuesday, September 16, 2008 at 12:00pm Eastern Time in New York City. Keynote speaker Dr. Peter Libby, Chief of Cardiovascular Medicine at the Brigham and Women's Hospital and Mallinckrodt Professor of Medicine at Harvard Medical School, will present "Inflammation in Atherosclerosis: Theory and Practice." Following Dr. Libby's presentation, Dr. Lawrence K. Cohen, chief executive officer of VIA Pharmaceuticals, will moderate an expert panel.

"We are pleased to have Dr. Libby speak about the importance of inflammation in atherosclerosis," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "While there are a number of currently available therapies that help reduce risk factors of heart disease, they do not address inflammation, an underlying cause of atherosclerosis and complications such as heart attack and stroke."

Dr. Libby is the Chief of Cardiovascular Medicine at the Brigham and Women's Hospital in Boston, Massachusetts and serves as the Mallinckrodt Professor of Medicine at Harvard Medical School. He also directs the D.W. Reynolds Cardiovascular Clinical Research Center at Harvard. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments. His areas of clinical expertise include general and preventive cardiology. Dr. Libby writes a cardiovascular blog, "Consults-Experts on the Front Lines of Medicine", for
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.524 03/2002 , ... , , , , ... , Cell type , Bacteria, ...
... , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.519 12/2001 , ... , , , ... , Cell type , Bacteria, gram positive, ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.520 12/2001 , ... , , , Microorganism , ... Cell type , Bacteria, gram positive, ...
Cached Biology Technology:Mycobacterium tuberculosis 2Lactococcus lactis 2Listeria monocytogenes 2
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... called microRNAs, control protein production primarily by causing the ... to be disabled by the cell, according to Whitehead ... microRNAs control protein production by causing the mRNAs to ... microRNAs impart by jamming the process that translates mRNAs ...
... Aug. 16, 2010 A very aggressive disease with ... higher exposure to estrogens, according to a group of ... Dr. Jan-ke Gustafsson, Robert A. Welch Professor in UH,s ... a paper titled "Estrogen-dependent gallbladder carcinogenesis in LXRβ-/- female ...
... WI, August 16th, 2010 - Fields amended with ... according to studies by USDA-Agricultural Research Service (ARS) ... about the agricultural pollutants that can build up ... nearby streams and rivers. Poultry producers ...
Cached Biology News:RNA snippets control protein production by disabling mRNAs 2RNA snippets control protein production by disabling mRNAs 3Gallbladder cancer may be linked to estrogens, says UH team 2Arsenic in field runoff linked to poultry litter 2
Request Info...
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
Request Info...
Biology Products: